Weill Cornell Medicine investigators report that BAF mutations can drive cancer by reshaping DNA accessibility to the regulatory protein CTCF. The work connects alterations in the chromatin remodeling machinery to changes in higher-order genome regulation. For cancer biology, the claim is mechanistically specific: BAF-driven changes influence CTCF access, which in turn can alter transcriptional programs and contribute to malignant progression. The study adds to a growing body of evidence that chromatin architecture regulators are not only prognostic markers but may act as upstream drivers of oncogenic regulatory rewiring. Therapeutic relevance will depend on whether this CTCF accessibility axis presents druggable vulnerabilities or biomarker strategies that can stratify patients with BAF alterations.